Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@article{Gaudet2015AntisenseIO,
  title={Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.},
  author={Daniel Gaudet and Veronica J Alexander and Brenda F. Baker and Diane Brisson and Karine Tremblay and Walter Singleton and Richard S. Geary and Steven G. Hughes and Nicholas J. Viney and Mark J. Graham and Rosanne M. Crooke and Joseph L. Witztum and John D. Brunzell and John J P Kastelein},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 5},
  pages={
          438-47
        }
}
BACKGROUND Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis. METHODS We conducted a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter (4.0 mmol per liter… 

Figures from this paper

The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Treatment of hypertriglyceridaemic subjects with AKCEA-APOCIII-LRx results in a broad improvement in the atherogenic lipid profile with a favourable safety and tolerability profile.

Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia

Volanesorsen effectively reduces TG in sHTG through a mechanism that is mainly LPL-independent, potentially decreasing the risk of AP and preserving the long-term utility of this drug.

Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)

Two new ASOs, volanesorsen targeting ApoC-III and IONIS-APO(a)LRx targeting apo(a), are promising new agents for the treatment of hypertriglyceridemia and hyperlipoproteinemia (a), respectively.

Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen

APOC3-targeted experimental treatments for dyslipidemia, a key regulator of TG metabolism and its targeting may reduce TG levels and cardiovascular risk, and M580, a retinoic acid receptor-α specific agonist, an agent in early-stage development are discussed.

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

The purpose of this review is to discuss the currently available therapies and to elaborate the most promising novel therapeutics for TG lowering to become players in the treatment for (especially) severe HTG in the near future.

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

Novel high-throughput ELISAs were developed to detect lipoprotein-associated apoC-III, including for the first time on Lp(a).

ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets

The role of Angiopoietin-like protein 3 and Apo C-III in lipid metabolism is evaluated, the latest clinical advances targeting those molecules are presented, and the remaining scientific challenges on residual lipid-associated cardiovascular risk are outlined.

The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?

This article aims to review the role of apoC-III and angptl3 in triglyceride metabolism and combine early clinical evidence of CVD reducing potential of these new therapeutic targets to confer more favorable CVD risk reduction.

Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.

Elevated apoCIII may play a role in the hypertriglyceridemia of lipodystrophy independent of leptin deficiency and replacement, and the effects of leptin replacement in lipody Strophy patients as an exploratory outcome were studied.
...

References

SHOWING 1-10 OF 50 REFERENCES

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

Mipomersen administered as monotherapy in subjects with mild-to-moderate hyperlipidaemia produced potent reductions in all apoB-containing lipoproteins and higher doses were associated with hepatic transaminase increases.

Targeting APOC3 in the familial chylomicronemia syndrome.

An inhibitor of APOC3 messenger RNA was administered to treat three patients with the familial chylomicronemia syndrome and triglyceride levels ranging from 1406 to 2083 mg per deciliter with treatment, and data support the role of AP OC3 as a key regulator of LPL-independent pathways of triglyceride metabolism.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Antisense inhibition of Apolipoprotein C-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease.

VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial

The plasma concentrations of V LDL particles and apoCIII in VLDL and LDL are more specific measures of coronary heart disease risk than plasma triglycerides perhaps because their known metabolic properties link them more closely to atherosclerosis.

A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-ch cholesterol and lower levels of LDL-cholesterol, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease.

Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype

A central role for apoC-III in metabolic defects leading to hypertriglyceridemia is supported, characterized by reduced clearance of triglyceride-rich lipoproteins and the formation of the dense LDL phenotype.